Whitehawk Therapeutics (NASDAQ:WHWK) Now Covered by B. Riley Financial

Investment analysts at B. Riley Financial assumed coverage on shares of Whitehawk Therapeutics (NASDAQ:WHWK) in a report issued on Thursday. The brokerage set a “buy” rating and a $10.00 price target on the stock. B. Riley Financial’s target price would indicate a potential upside of 127.79% from the stock’s current price.

Several other equities research analysts have also recently issued reports on WHWK. Citizens Jmp initiated coverage on Whitehawk Therapeutics in a report on Thursday, April 16th. They issued a “market outperform” rating and a $8.00 price objective on the stock. Oppenheimer reissued an “outperform” rating and set a $7.00 target price on shares of Whitehawk Therapeutics in a report on Friday, May 8th. Citigroup started coverage on Whitehawk Therapeutics in a research report on Thursday, April 16th. They issued an “outperform” rating on the stock. Wall Street Zen lowered Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Finally, Weiss Ratings downgraded Whitehawk Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, June 5th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Whitehawk Therapeutics Stock Performance

Shares of NASDAQ WHWK opened at $4.39 on Thursday. The firm has a market cap of $217.09 million, a PE ratio of -2.61 and a beta of 0.77. The firm has a fifty day moving average of $4.27 and a 200 day moving average of $3.46. Whitehawk Therapeutics has a one year low of $1.57 and a one year high of $5.49.

Whitehawk Therapeutics (NASDAQ:WHWK) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.04. On average, equities analysts predict that Whitehawk Therapeutics will post -1.44 EPS for the current fiscal year.

Insider Activity at Whitehawk Therapeutics

In other Whitehawk Therapeutics news, insider Bryan Ball sold 92,460 shares of the company’s stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $3.64, for a total value of $336,554.40. Following the completion of the sale, the insider directly owned 397,106 shares in the company, valued at $1,445,465.84. This represents a 18.89% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Scott M. Giacobello sold 141,600 shares of the firm’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $4.13, for a total value of $584,808.00. Following the completion of the sale, the chief financial officer directly owned 295,224 shares of the company’s stock, valued at $1,219,275.12. This trade represents a 32.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 695,830 shares of company stock valued at $2,553,026. 49.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Whitehawk Therapeutics

A number of hedge funds have recently modified their holdings of WHWK. Avoro Capital Advisors LLC acquired a new stake in Whitehawk Therapeutics during the third quarter worth about $5,414,000. Suvretta Capital Management LLC acquired a new stake in shares of Whitehawk Therapeutics during the 3rd quarter worth approximately $7,030,000. Ally Bridge Group NY LLC acquired a new stake in shares of Whitehawk Therapeutics during the 3rd quarter worth approximately $1,554,000. Eversept Partners LP purchased a new stake in shares of Whitehawk Therapeutics during the 4th quarter valued at approximately $630,000. Finally, Geode Capital Management LLC raised its position in shares of Whitehawk Therapeutics by 11.4% during the 4th quarter. Geode Capital Management LLC now owns 425,440 shares of the company’s stock valued at $1,030,000 after buying an additional 43,686 shares during the period. Hedge funds and other institutional investors own 52.08% of the company’s stock.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.